Gabriele Valentini

Gabriele Valentini

Auto-generated profile, based on publicly available information

Gabriele Valentini

Department of Precision Medicine, Section of Rheumatology, University of Campania Luigi Vanvitelli, Naples, Italy

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
FHFrank van Den Hoogen
Frank van Den Hoogen
DKDinesh Khanna
Dinesh Khanna
JFJaap Fransen
Jaap Fransen
SJSindhu R. Johnson
Sindhu R. Johnson
MBMurray Baron
Murray Baron
JPJanet E Pope
Janet E Pope
Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present work, by a joint ...

1 October 2010 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
ATAnthony J Tyndall
Anthony J Tyndall
BBBettina Bannert
Bettina Bannert
MVMadelon Vonk
Madelon Vonk
PAPaolo Airò
Paolo Airò
FCFranco Cozzi
Franco Cozzi
UWUlrich A Walker
Ulrich A Walker
Objectives To determine the causes and predictors of mortality in systemic sclerosis (SSc). Methods Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria and prospectively followed in the EULAR Scleroderma Trials and Research (EUSTAR) cohort were analysed. EUSTAR centres completed a structured questionnaire on cause of death and comorbidities. Kaplan–Meier and Cox proportional hazards models were used to analyse survival in SSc subgroups and to identify predictors of mortality. Results Questionnaires were obtained on 234 of 284 fatalities. 55% of deaths were attributed directly to SSc and 41% to non-SSc causes; in 4% the cause of death was not assigned. Of the SSc-related deaths, 35% were attributed to pulmonary fibrosis, 26% to pulmonary arterial hypertension (PAH) and 26% to cardiac causes (mainly heart failure and arrhythmias). Among the non-SSc-related causes, infections (33%) and malignancies (31%) were followed by cardiovascular causes (29%). Of the non-SSc-related fatalities, 25% died of causes in which SSc-related complications may have participated (pneumonia, sepsis and gastrointestinal haemorrhage). Independent risk factors for mortality and their HR were: proteinuria (HR 3.34), the presence of PAH based on echocardiography (HR 2.02), pulmonary restriction (forced vital capacity below 80% of normal, HR 1.64), dyspnoea above New York Heart Association class II (HR 1.61), diffusing capacity of the lung (HR 1.20 per 10% decrease), patient age at onset of Raynaud's phenomenon (HR 1.30 per 10 years) and the modified Rodnan skin score (HR 1.20 per 10 score points). Conclusion Disease-related causes, in particular pulmonary fibrosis, PAH and cardiac causes, accounted for the majority of deaths in SSc.

1 August 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
OKOtylia Kowal-Bielecka
Otylia Kowal-Bielecka
JFJaap Fransen
Jaap Fransen
JAJerome Avouac
Jerome Avouac
MBMike Becker
Mike Becker
AKAgnieszka Kulak
Agnieszka Kulak
UMUlf Müller-Ladner
Ulf Müller-Ladner

1 March 2002 in Medicine
Verified
Journal Article
Closed access
CFClodoveo Ferri
Clodoveo Ferri
GVGabriele Valentini
Gabriele Valentini
FCFranco Cozzi
Franco Cozzi
Marco SebastianiMarco Sebastiani
Marco Sebastiani
CMClaudio Michelassi
Claudio Michelassi
GTGiuseppe Tirri
Giuseppe Tirri

1 May 2009 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
OKO Kowal-Bielecka
O Kowal-Bielecka
RLR Landewé
R Landewé
JAJérôme Avouac
Jérôme Avouac
SCS Chwiesko
S Chwiesko
IMI Miniati
I Miniati
MMMarco Matucci-Cerinic
Marco Matucci-Cerinic

1 July 2009 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
KVK Visser
K Visser
WKW Katchamart
W Katchamart
ELE Loza
E Loza
JMJ A Martinez-Lopez
J A Martinez-Lopez
CSC Salliot
C Salliot
MDM Dougados
M Dougados
To develop evidence-based recommendations for the use of methotrexate in daily clinical practice in rheumatic disorders. 751 rheumatologists from 17 countries participated in the 3E (Evidence, Expertise, Exchange) Initiative of 2007-8 consisting of three separate rounds of discussions and Delphi votes. Ten clinical questions concerning the use of methotrexate in rheumatic disorders were formulated. A systematic literature search in Medline, Embase, Cochrane Library and 2005-7 American College of Rheumatology/European League Against Rheumatism meeting abstracts was conducted. Selected articles were systematically reviewed and the evidence was appraised according to the Oxford levels of evidence. Each country elaborated a set of national recommendations. Finally, multinational recommendations were formulated and agreement among the participants and the potential impact on their clinical practice was assessed. A total of 16 979 references was identified, of which 304 articles were included in the systematic reviews. Ten multinational key recommendations on the use of methotrexate were formulated. Nine recommendations were specific for rheumatoid arthritis (RA), including the work-up before initiating methotrexate, optimal dosage and route, use of folic acid, monitoring, management of hepatotoxicity, long-term safety, mono versus combination therapy and management in the perioperative period and before/during pregnancy. One recommendation concerned methotrexate as a steroid-sparing agent in other rheumatic diseases. Ten recommendations for the use of methotrexate in daily clinical practice focussed on RA were developed, which are evidence based and supported by a large panel of rheumatologists, enhancing their validity and practical use.